Ibiamox (Amoxicillin) 250 mg & 500 mg – Uses, Dosage for ENT, Respiratory, Urinary & Skin Infections Guide

Ibiamox® (Amoxicillin)

1. Disclaimer

This information is provided for educational and reference purposes only and is not a substitute for the prescribing information, official package leaflet, or individualized advice from a qualified healthcare professional. Antibiotic selection, dose, duration, and suitability should be based on the infection, patient characteristics, renal function, local resistance patterns, and antimicrobial susceptibility results when available.

We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.

2. Summary

Ibiamox® is an oral antibacterial medicine containing amoxicillin, a semisynthetic aminopenicillin and beta-lactam antibiotic. It is used for susceptible bacterial infections involving, among other sites, the ear, nose and throat, lower respiratory tract, urinary/genitourinary tract, and skin and soft tissues. Amoxicillin should be used only when a bacterial infection is proven or strongly suspected, because unnecessary antibiotic exposure contributes to antimicrobial resistance.

3. Brand Name

Ibiamox®

The active ingredient is amoxicillin. Current Egyptian medicine databases identify Ibiamox as an Amoun product.

4. Category

Therapeutic class: Antibacterial / anti-infective
Pharmacological class: Penicillin-class beta-lactam antibiotic; aminopenicillin
Egyptian classification: Penicillins – monocomponent.

5. Active Ingredient

Amoxicillin, supplied as amoxicillin trihydrate in the oral dosage forms described for the product. Amoxicillin is bactericidal against susceptible bacteria by interfering with bacterial cell-wall biosynthesis.

6. Pharmaceutical Form & Strength

Current Egyptian medicine databases identify the following Ibiamox presentations:

• Capsules: 250 mg and 500 mg
• Powder for oral suspension: 200 mg/5 mL, 250 mg/5 mL, and 400 mg/5 mL. The 200 mg/5 mL and 400 mg/5 mL strengths are also listed in 80 mL presentations in Egyptian medicine listings.

The concentration stated for an oral suspension refers to the amount of amoxicillin contained in each 5 mL after reconstitution.

7. Manufacturer & Marketing Authorization Holder

Manufacturer:
Amoun Pharmaceutical Industries Co., S.A.E., Egypt
El Obour City, Cairo, Egypt.

Current Egyptian and international medicine databases identify Amoun Pharmaceutical Industries as the manufacturer/laboratory associated with Ibiamox.

The manufacturer should be distinguished from the dispensing pharmacy or online seller. The legally current marketing-authorization-holder status should be verified against the latest Egyptian Authority for Drug Administration (EDA) registration or official product information.

8. Mechanism of Action

Amoxicillin is a beta-lactam antibacterial. It acts during the active multiplication of susceptible bacteria by inhibiting bacterial cell-wall biosynthesis, ultimately causing bacterial cell death. Bacterial resistance is commonly mediated by beta-lactamase enzymes, which can inactivate amoxicillin by hydrolyzing its beta-lactam ring.

9. Spectrum of Activity

Amoxicillin has activity against a range of susceptible Gram-positive and Gram-negative organisms, but “broad spectrum” does not mean that all strains of the organisms below are susceptible.

Organisms identified in current prescribing information as susceptible targets, depending on the infection and isolate, include:

Gram-positive bacteria

• Enterococcus faecalis
• Staphylococcus spp. — susceptible strains
• Streptococcus pneumoniae
• Streptococcus spp., including susceptible alpha- and beta-hemolytic streptococci

Gram-negative bacteria

• Escherichia coli — susceptible strains
• Haemophilus influenzae — susceptible strains
• Proteus mirabilis — susceptible strains

Helicobacter pylori is also a clinically relevant target of amoxicillin in specific eradication regimens.

Resistance, especially through beta-lactamase production, is clinically important. The historical listing of organisms such as Neisseria gonorrhoeae, Salmonella, and Shigella should not be interpreted as evidence that amoxicillin remains an appropriate empiric treatment for these infections. In particular, current CDC guidance recommends ceftriaxone rather than amoxicillin for uncomplicated gonorrhea.

10. Pharmacokinetics

Amoxicillin is acid-stable and is rapidly absorbed after oral administration. Peak blood concentrations generally occur approximately 1–2 hours after administration. For 250 mg and 500 mg oral doses, mean peak concentrations have been reported in the approximate ranges of 3.5–5.0 mcg/mL and 5.5–7.5 mcg/mL, respectively.

Amoxicillin is distributed into many tissues and body fluids and is approximately 20% protein-bound in serum. Its elimination half-life is approximately 61 minutes, and about 60% of an orally administered dose is excreted in urine within 6–8 hours, largely as unchanged drug. Renal impairment therefore has an important effect on clearance.

11. Indications

Ibiamox/amoxicillin may be used for bacterial infections caused by susceptible organisms, including appropriately selected:

• Ear, nose and throat infections involving susceptible organisms
• Lower respiratory tract infections caused by susceptible organisms
• Selected urinary/genitourinary tract infections
• Selected skin and skin-structure infections
• H. pylori infection in combination with other appropriate eradication medicines in indicated adult patients

The older blanket wording “gonorrhea” should not be retained as a current routine indication: antimicrobial resistance has made amoxicillin unsuitable for empiric treatment of uncomplicated gonorrhea. Current CDC guidance recommends ceftriaxone-based treatment.

Likewise, “typhoid fever” should not be presented as an unconditional indication. Amoxicillin should only be considered where the organism is susceptible and treatment is consistent with current local epidemiology and treatment guidance.

12. Administration

Ibiamox is administered orally.

Capsules should be swallowed as prescribed. Oral suspension should be shaken well before every dose and measured with an appropriate calibrated oral syringe or measuring device.

To minimize gastrointestinal intolerance, current prescribing information recommends taking amoxicillin at the start of a meal.

The exact dosage and dosing interval depend on the infection, its severity, age/weight, renal function, and local treatment recommendations.

For adults and pediatric patients aged 3 months and older weighing more than 40 kg, current prescribing information gives the following representative regimens:

• Ear/nose/throat, skin/skin-structure, and genitourinary infections, mild/moderate: 500 mg every 12 hours or 250 mg every 8 hours.
• The same infections, severe: 875 mg every 12 hours or 500 mg every 8 hours.
• Lower respiratory tract infections: 875 mg every 12 hours or 500 mg every 8 hours.

For pediatric patients aged 3 months and older weighing less than 40 kg:

• Mild/moderate infections: 25 mg/kg/day divided every 12 hours or 20 mg/kg/day divided every 8 hours.
• Severe infections or lower respiratory tract infections: 45 mg/kg/day divided every 12 hours or 40 mg/kg/day divided every 8 hours.

For infants aged 12 weeks (3 months) or younger, the recommended upper dose is 30 mg/kg/day divided every 12 hours, because renal elimination is not fully developed.

For adults, the current prescribing information summarizes usual overall dosing as approximately 750–1750 mg/day in divided doses every 8–12 hours, but infection-specific regimens should be followed rather than treating this range as a universal dose.

For H. pylori, amoxicillin must be used as part of a defined combination regimen. The U.S. product label includes adult amoxicillin doses of 1 g twice daily with clarithromycin and lansoprazole for 14 days as triple therapy, or 1 g three times daily with lansoprazole for 14 days as dual therapy. However, current ACG guidance recommends 14-day optimized bismuth quadruple therapy as the preferred empiric regimen for treatment-naïve adults when susceptibility is unknown, with rifabutin-based triple therapy and vonoprazan-amoxicillin dual therapy as alternative suggested regimens.

Treatment should generally continue for the prescribed duration; current prescribing information recommends at least 10 days for infections caused by Streptococcus pyogenes to prevent acute rheumatic fever.

13. Method of Preparation

For the powder for oral suspension:

1. Loosen the powder by tapping the bottle until the powder flows freely.
2. Add the required amount of water according to the current Ibiamox bottle mark and package instructions.
3. Shake vigorously.
4. If the manufacturer's instructions specify staged addition of water, follow those instructions precisely.
5. Shake thoroughly before every dose.

The exact volume of water must not be inferred from a different amoxicillin brand or a different bottle size because reconstitution volumes are formulation- and bottle-specific. Current amoxicillin labeling demonstrates that the required water volume varies according to the concentration and bottle size.

14. Contraindications

Amoxicillin is contraindicated in patients who have experienced a serious hypersensitivity reaction such as anaphylaxis or Stevens–Johnson syndrome to amoxicillin or to another beta-lactam antibacterial drug, including penicillins or cephalosporins.

15. Warnings & Precautions

Important precautions include:

• Serious allergic reactions: anaphylaxis can occur and may occasionally be fatal.
• Severe cutaneous adverse reactions: including Stevens–Johnson syndrome, toxic epidermal necrolysis, DRESS and AGEP.
• Drug-induced enterocolitis syndrome (DIES): a rare non-IgE-mediated hypersensitivity reaction reported particularly in pediatric patients and characterized by prolonged vomiting, sometimes with hypotension or shock.
• Clostridioides difficile-associated diarrhea: may range from mild diarrhea to severe or fatal colitis and may occur during treatment or after treatment.
• Infectious mononucleosis: a high percentage of patients with mononucleosis who receive amoxicillin develop a prominent skin rash; amoxicillin should therefore not be administered to such patients.
• Antimicrobial resistance: treatment should be limited to proven or strongly suspected bacterial infections.

Dose adjustment is important in severe renal impairment. Patients with a GFR below 30 mL/min should not receive the 875-mg dose. Current labeling recommends lower doses and/or longer dosing intervals in severe renal impairment.

16. Drug Interactions

Clinically relevant interactions include:

• Probenecid: decreases renal tubular secretion of amoxicillin and may increase and prolong amoxicillin blood concentrations; concomitant use is not recommended in current product labeling.
• Oral anticoagulants: abnormal prolongation of prothrombin time/INR has been reported; monitoring and possible anticoagulant dose adjustment may be necessary.
• Allopurinol: concurrent administration increases the incidence of rash.
• Hormonal oral contraceptives: current U.S. product labeling states that amoxicillin may reduce the efficacy of combined oral estrogen/progestin contraceptives. However, contemporary clinical guidance generally does not consider amoxicillin itself to be a clinically important cause of contraceptive failure; vomiting or significant diarrhea can independently reduce the effectiveness of oral contraceptives.
• Other antibacterials: chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin in vitro, although the clinical significance of this interaction is not well established.

Patients taking anticoagulants, methotrexate, or multiple prescription medicines should have their medication list reviewed by a healthcare professional before treatment.

17. Side Effects

Common adverse effects include:

• Diarrhea
• Nausea
• Vomiting
• Skin rash

These were the most common adverse reactions reported in clinical trials of amoxicillin capsules, occurring in more than 1% of patients.

Less common but potentially serious reactions include severe allergic reactions/anaphylaxis, angioedema, severe cutaneous adverse reactions, C. difficile-associated colitis, liver injury, hematologic abnormalities, crystalluria, and neurological reactions such as seizures, particularly in appropriate risk settings or with excessive exposure. Tooth discoloration has also been reported, particularly in pediatric patients.

Immediate medical attention is warranted for breathing difficulty, facial or throat swelling, extensive or blistering rash, mucosal lesions, severe persistent diarrhea, or other signs of a serious hypersensitivity reaction.

18. Use in Special Populations

Children: Amoxicillin can be used in pediatric patients when appropriately indicated. Dosing should be based on age, body weight, infection, and renal function. In very young infants, renal immaturity delays elimination and requires a specific regimen. Current labeling recommends an upper dose of 30 mg/kg/day divided every 12 hours for infants aged 12 weeks or younger.

Pregnancy: Available human and clinical information has not established a clear teratogenic signal with amoxicillin. However, official prescribing information recommends that amoxicillin be used during pregnancy when clearly needed and clinically appropriate.

Breastfeeding: Amoxicillin is excreted into human milk. It is generally considered compatible with breastfeeding when clinically indicated, although the infant may rarely develop diarrhea, rash, or other signs of sensitization and should be observed appropriately.

Older adults: Clinical analyses have not identified major differences in response between older and younger patients, but greater sensitivity in some older individuals cannot be excluded. Because amoxicillin is substantially eliminated by the kidneys, renal function should be considered carefully when selecting the dose.

Renal impairment: Dose and/or dosing interval may require adjustment, particularly when GFR is below 30 mL/min. Specific reduced regimens are recommended for severe renal impairment and hemodialysis.

19. Storage Conditions

Unreconstituted powder: Store according to the current Ibiamox package instructions and protect the powder from excessive heat and moisture. Current amoxicillin labeling commonly specifies controlled room-temperature storage for the dry powder.

After reconstitution: Keep the bottle tightly closed and shake well before each use. Current amoxicillin suspension labeling commonly specifies that unused reconstituted suspension should be discarded after 14 days; refrigeration is generally preferable but not always required. Because storage instructions can be product/formulation-specific, the current Ibiamox leaflet and bottle instructions should take precedence if they specify different conditions.

Keep all medicines out of the reach of children.

20. Additional Sections

Antibiotic stewardship

Antibiotic stewardship: Ibiamox should not be used for viral infections such as uncomplicated viral colds or influenza. Unnecessary antibiotic use contributes to antimicrobial resistance.

Infective endocarditis prophylaxis

Infective endocarditis prophylaxis: Amoxicillin is not a general-purpose indication for preventing endocarditis. Current American Heart Association recommendations restrict dental antibiotic prophylaxis to selected patients with cardiac conditions at the highest risk of an adverse outcome from viridans-group streptococcal infective endocarditis undergoing qualifying dental procedures. When indicated, the regimen is a single 2-g oral dose in adults, 30–60 minutes before the procedure; pediatric dosing is 50 mg/kg.

Gonorrhea

Gonorrhea: Amoxicillin should not be presented as a current empiric first-line treatment for uncomplicated gonorrhea because of antimicrobial resistance. Current CDC guidance recommends ceftriaxone as the recommended treatment.

H. pylori

H. pylori: Amoxicillin remains an important component of several eradication regimens, but it should not be used alone. Current ACG guidance recommends optimized bismuth quadruple therapy for 14 days as the preferred empiric treatment for treatment-naïve adults when susceptibility is unknown, while other amoxicillin-containing regimens may be appropriate in selected circumstances.

21. Frequently Asked Questions (FAQ)

Is Ibiamox the same as amoxicillin?

Yes. Ibiamox is a branded product containing amoxicillin.

Can Ibiamox be used for a cold or influenza?

No. These illnesses are usually viral, and amoxicillin should be reserved for bacterial infections for which it is clinically appropriate.

Can the suspension be taken without shaking?

No. The suspension should be shaken well before every dose to help ensure uniform dosing.

Can amoxicillin be taken during pregnancy?

Amoxicillin may be used during pregnancy when clinically indicated and prescribed by a healthcare professional. Current prescribing information recommends use when clearly needed.

Can it be used while breastfeeding?

Generally yes. Amoxicillin passes into breast milk, but it is commonly considered compatible with breastfeeding when clinically indicated; the infant should be observed for uncommon diarrhea, rash, or sensitization.

Is amoxicillin still recommended for gonorrhea?

No. It should not be considered a routine empiric treatment. Current CDC guidance recommends ceftriaxone for uncomplicated gonorrhea.

How long should treatment continue?

The duration varies according to the infection, its severity, the causative organism, and the prescribed regimen. Treatment should follow the prescribed course rather than being shortened or extended without medical advice. Current labeling recommends at least 10 days for infections caused by Streptococcus pyogenes to prevent acute rheumatic fever.

22. References

1. DailyMed / U.S. National Library of Medicine. Amoxicillin Capsules, USP — Full Prescribing Information. Revised March 2026. Includes current indications, dosage, contraindications, warnings, adverse reactions, interactions, special populations, mechanism of action, pharmacokinetics, and renal dosing.
2. DailyMed. Amoxicillin for Oral Suspension — Prescribing Information. Current labeling for reconstitution, administration, and post-reconstitution storage.
3. American College of Gastroenterology (ACG). ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. American Journal of Gastroenterology. 2024;119(9):1730–1753.
4. American College of Gastroenterology. ACG Guideline on Treatment of Helicobacter pylori: New Recommendations… Will Practice Change? September 17, 2024.
5. Centers for Disease Control and Prevention (CDC). Gonococcal Infections Among Adolescents and Adults — STI Treatment Guidelines. Current CDC guidance recommends ceftriaxone for uncomplicated gonorrhea.
6. American Heart Association (AHA). Prevention of Infective Endocarditis — Antibiotic Prophylactic Regimens for Dental Procedures. Amoxicillin 2 g orally as a single dose 30–60 minutes before qualifying dental procedures in appropriate high-risk cardiac patients.
7. Vademecum / Egyptian medicine listings. Current listings for Ibiamox associated with Amoun Pharmaceutical Industries, including 250 mg and 500 mg capsules and oral suspension strengths including 200 mg/5 mL, 250 mg/5 mL, and 400 mg/5 mL.